X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (48149) 48149
Book Review (6297) 6297
Publication (2036) 2036
Newsletter (146) 146
Conference Proceeding (96) 96
Book Chapter (70) 70
Dissertation (23) 23
Magazine Article (19) 19
Book / eBook (10) 10
Newspaper Article (5) 5
Web Resource (4) 4
Government Document (2) 2
Data Set (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (43755) 43755
humans (40641) 40641
female (26726) 26726
antineoplastic combined chemotherapy protocols - therapeutic use (23040) 23040
oncology (22729) 22729
male (22584) 22584
cisplatin (21661) 21661
middle aged (21044) 21044
cisplatin - administration & dosage (19606) 19606
aged (17918) 17918
chemotherapy (17146) 17146
adult (16822) 16822
cancer (13388) 13388
cisplatin - therapeutic use (9275) 9275
treatment outcome (9083) 9083
combined modality therapy (7709) 7709
animals (7139) 7139
antineoplastic agents - therapeutic use (7135) 7135
lung neoplasms - drug therapy (6907) 6907
antineoplastic combined chemotherapy protocols - adverse effects (6716) 6716
neoplasm staging (6679) 6679
cisplatin - adverse effects (5802) 5802
prognosis (5369) 5369
survival rate (5257) 5257
carcinoma (5235) 5235
fluorouracil - administration & dosage (5020) 5020
pharmacology & pharmacy (4693) 4693
care and treatment (4620) 4620
carcinoma, non-small-cell lung - drug therapy (4454) 4454
radiotherapy (4314) 4314
aged, 80 and over (4291) 4291
drug administration schedule (4256) 4256
retrospective studies (4075) 4075
survival analysis (4051) 4051
apoptosis (4018) 4018
mice (3966) 3966
survival (3926) 3926
ovarian neoplasms - drug therapy (3918) 3918
therapy (3870) 3870
disease-free survival (3866) 3866
carcinoma, squamous cell - drug therapy (3790) 3790
cell line, tumor (3741) 3741
surgery (3643) 3643
etoposide - administration & dosage (3607) 3607
cisplatin - pharmacology (3567) 3567
doxorubicin - administration & dosage (3550) 3550
chemotherapy, adjuvant (3429) 3429
research (3402) 3402
tumors (3396) 3396
follow-up studies (3391) 3391
paclitaxel (3367) 3367
lung neoplasms - pathology (3344) 3344
carboplatin (3276) 3276
trial (3179) 3179
analysis (3130) 3130
deoxycytidine - analogs & derivatives (3124) 3124
antineoplastic agents - pharmacology (3029) 3029
carboplatin - administration & dosage (2950) 2950
paclitaxel - administration & dosage (2943) 2943
abridged index medicus (2934) 2934
medicine & public health (2902) 2902
antineoplastic agents - administration & dosage (2852) 2852
adenocarcinoma - drug therapy (2834) 2834
adolescent (2745) 2745
antineoplastic agents (2655) 2655
antineoplastic combined chemotherapy protocols - administration & dosage (2646) 2646
antineoplastic agents - adverse effects (2643) 2643
dose-response relationship, drug (2633) 2633
health aspects (2592) 2592
expression (2535) 2535
stomach neoplasms - drug therapy (2521) 2521
gemcitabine (2488) 2488
deoxycytidine - administration & dosage (2450) 2450
ovarian cancer (2449) 2449
toxicity (2428) 2428
metastasis (2420) 2420
time factors (2407) 2407
antimitotic agents (2352) 2352
cyclophosphamide - administration & dosage (2283) 2283
prospective studies (2275) 2275
doxorubicin (2257) 2257
hematology, oncology and palliative medicine (2252) 2252
combination (2245) 2245
lung cancer (2233) 2233
vinblastine - administration & dosage (2228) 2228
phase-ii (2184) 2184
cancer therapies (2166) 2166
carcinoma, non-small-cell lung - pathology (2146) 2146
remission induction (2119) 2119
apoptosis - drug effects (2112) 2112
carcinoma, squamous cell - pathology (2077) 2077
5-fluorouracil (2047) 2047
drug therapy (2032) 2032
etoposide (1992) 1992
neoplasms - drug therapy (1978) 1978
radiation-therapy (1975) 1975
ovarian neoplasms - pathology (1961) 1961
obstetrics & gynecology (1946) 1946
docetaxel (1926) 1926
lung neoplasms - mortality (1921) 1921
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (43059) 43059
Japanese (2989) 2989
French (644) 644
Chinese (543) 543
German (468) 468
Russian (182) 182
Italian (138) 138
Spanish (137) 137
Polish (77) 77
Hungarian (31) 31
Dutch (22) 22
Czech (18) 18
Bulgarian (17) 17
Ukrainian (13) 13
Korean (12) 12
Hebrew (11) 11
Portuguese (9) 9
Romanian (9) 9
Danish (7) 7
Serbian (6) 6
Lithuanian (5) 5
Norwegian (4) 4
Finnish (3) 3
Slovak (3) 3
Swedish (2) 2
Turkish (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 1, pp. 142 - 150
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 141 - 148
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung | Lung cancer | Diarrhea | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | ADVANCED SOLID TUMORS | CANCER-PATIENTS | AMPLIFICATION | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CARCINOMA | FACTOR/SCATTER FACTOR | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Journal Article